Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

Core Insights - Eledon Pharmaceuticals will present topline results from the Phase 2 BESTOW trial for tegoprubart at the American Society of Nephrology's Kidney Week 2025 Annual Meeting [1][2] - The oral presentation is scheduled for November 6, 2025, focusing on the efficacy and safety of tegoprubart in preventing rejection in kidney transplantation [2] - A conference call to discuss the trial results will be held on November 7, 2025, at 8:00 a.m. ET [3] Company Overview - Eledon Pharmaceuticals is a clinical stage biotechnology company developing immune-modulating therapies for life-threatening conditions [4] - The lead investigational product, tegoprubart, is an anti-CD40L antibody targeting CD40 Ligand, which has significant therapeutic potential [4] - The company is conducting studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS) [4]